--- title: "Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook" type: "News" locale: "en" url: "https://longbridge.com/en/news/285494299.md" description: "Royalty Pharma plc (RPRX) reported a rise in Q1 earnings, with net income before tax increasing to $468 million from $434 million. Operating income also grew to $563 million from $534 million. Net income attributable to the company climbed to $295 million, while total income rose to $631 million. Income from financial royalty assets increased to $595 million. The company raised its full-year Portfolio Receipts outlook to between $3.325 billion and $3.450 billion, up from the previous estimate of $3.275 billion - $3.425 billion." datetime: "2026-05-07T06:20:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285494299.md) - [en](https://longbridge.com/en/news/285494299.md) - [zh-HK](https://longbridge.com/zh-HK/news/285494299.md) --- # Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook Add as your preferred news source on Google Add Now Royalty Pharma plc (RPRX) on Thursday reported higher first-quarter earnings, supported mainly by growth in income from financial royalty assets. Net income before tax increased to $468 million from $434 million previously. Operating income rose to $563 million from $534 million in the prior-year quarter. Net income attributable to Royalty Pharma climbed to $295 million from $239 million a year earlier. Total income and other revenues grew to $631 million from $568 million last year. Income from financial royalty assets increased to $595 million from $539 million, while other royalty income and revenues rose to $36 million from $29 million. The company said Royalty Receipts grew 13% to $887 million in the first quarter, driven by Tremfya, Voranigo and Evrysdi. Portfolio Receipts increased by 10% to $925 million. For the full year, Royalty Pharma now expects Portfolio Receipts to be between $3.325 billion and $3.450 billion, up from the prior outlook of $3.275 billion - $3.425 billion. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) ## Related News & Research - [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md) - [](https://longbridge.com/en/news/286807703.md) - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md) - [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md) - [](https://longbridge.com/en/news/286601439.md)